daunorubicin has been researched along with alpha-aminopyridine in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, K; Deng, M; Deng, S; Li, J; Li, P; Li, Y; Wang, Y; Xu, B; Zhang, L; Zhou, Y | 1 |
| Tiong, IS; Wei, AH | 2 |
| Chmielewska, K; Kluska, M; Pietrzak, J; Robaszkiewicz, A; Rygielska, Ż; Tempka, D; Tokarz, P; Virág, L | 1 |
| Sweet, K; Talati, C | 1 |
| Bukum, N; Hofman, J; Morell, A; Novotna, E; Wsol, V | 1 |
| DiNardo, C; Guerra, VA; Konopleva, M | 1 |
| DiNardo, CD; Wei, AH | 1 |
| Arber, DA; Erba, HP | 1 |
| Cerchione, C; Martinelli, G | 1 |
| Thol, F | 1 |
5 review(s) available for daunorubicin and alpha-aminopyridine
| Article | Year |
|---|---|
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Liposomes; Molecular Targeted Therapy; Mutation; Proto-Oncogene Proteins c-bcl-2; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Treatment Outcome; Triazines | 2017 |
Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Cytarabine; Daunorubicin; Female; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Pyridines; Staurosporine; Triazines | 2018 |
New drugs creating new challenges in acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Pyrazines; Pyridines; Staurosporine; Triazines; United States; United States Food and Drug Administration | 2019 |
Venetoclax-based therapies for acute myeloid leukemia.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cytarabine; Daunorubicin; Glycine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sulfonamides; Triazines | 2019 |
Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC).
Topics: Aged; Aminopyridines; Antineoplastic Agents; Blood Cells; Bone Marrow; Bone Marrow Examination; Chromosome Aberrations; Cytarabine; Cytogenetic Analysis; Daunorubicin; DNA Mutational Analysis; Genetic Predisposition to Disease; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; PubMed; Triazines | 2020 |
7 other study(ies) available for daunorubicin and alpha-aminopyridine
| Article | Year |
|---|---|
Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytarabine; Daunorubicin; DNA Damage; DNA Repair; Drug Therapy; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Neoplastic Stem Cells; Young Adult | 2017 |
Downregulation of PARP1 transcription by CDK4/6 inhibitors sensitizes human lung cancer cells to anticancer drug-induced death by impairing OGG1-dependent base excision repair.
Topics: Aminopyridines; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Daunorubicin; DNA Damage; DNA Glycosylases; DNA Repair; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Hydrogen Peroxide; Lung Neoplasms; Piperazines; Poly (ADP-Ribose) Polymerase-1; Promoter Regions, Genetic; Purines; Pyridines | 2018 |
In brief: Two new drugs for AML.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Enzyme Inhibitors; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Liposomes; Mutation; Treatment Outcome; Triazines | 2018 |
Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3.
Topics: Aldo-Keto Reductase Family 1 Member C3; Aldo-Keto Reductases; Aminopyridines; Binding Sites; Catalytic Domain; Daunorubicin; HCT116 Cells; Humans; Inhibitory Concentration 50; Kinetics; Molecular Docking Simulation; Morpholines; Recombinant Proteins | 2019 |
How I treat acute myeloid leukemia in the era of new drugs.
Topics: Adult; Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Mutation; Prognosis; Pyrazines; Pyridines; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Triazines | 2020 |
Acute leukemias in 2020: state of the art.
Topics: Acute Disease; Aminopyridines; Antineoplastic Agents; Antineoplastic Agents, Immunological; Congresses as Topic; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Glycine; Humans; Leukemia; Pyridines; Recombinant Fusion Proteins; Staurosporine; Triazines | 2020 |
What to use to treat AML: the role of emerging therapies.
Topics: Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Approval; Drug Discovery; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Pyrazines; Pyridines; Triazines | 2021 |